NASDAQ: AURA

Aura Biosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for AURA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Aura Biosciences, Inc. (NASDAQ: AURA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:16 UTC.

What Aura Biosciences, Inc. does

This clinical-stage biotechnology company develops precision therapies designed to treat solid tumors while preserving organ function. The company's lead candidate, bel-sar, is a virus-like drug conjugate that works through a dual mechanism: delivering cytotoxic payloads to cancer cells and triggering an immune response. Bel-sar is in late-stage development for early choroidal melanoma as a potential vision-sparing alternative to current treatments like radiotherapy and surgical removal, with Phase 2 data showing an 80% tumor control rate and 90% visual acuity preservation.

Summarized from Aura Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for AURA are available in Oxford Ledge.
Open AURA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-01

2026-09-01Chief Operating OfficerAward134,513—
2026-09-01SVP, Finance & PAOAward23,540—
2026-09-01Chief Reg. & Quality OfficerStock Option (Right to Buy)Award199,115—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

TCG Crossover Management, LLC9,533,333$67.69MNEW
MONTANOVA CAPITAL, LLC7,206,217$51.16M+64.8%
Frazier Life Sciences Management, L.P.7,100,000$50.41M+39.2%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-05-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-05-15Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-04-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersDe Rosch'sEstimatedSEC 8-K →

Company news

View all →

Aura Biosciences to Participate in Upcoming Investor Conference
globenewswire.com2026-09-02
Fewer than five qualifying stories — full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AURA and 5,000+ tickers.

Create a free account — keep AURA

For your agent

GET /api/data?ticker=AURA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt